SRI International Executive Walter Moos to Discuss Collaborative Pharmaceutical Opportunities with a Nonprofit Organization at BIO-Europe 2010
WHAT:
A presentation on strategic collaboration opportunities with SRI's Biosciences Division. SRI's well-funded researchers operateas a nonprofit pharmaceutical organization and have the resources to provide complete drug discovery and development capabilities — from "Idea to IND®." SRI is currently seeking partners at all preclinical phases of basic research, drug discovery, pharmaceutical sciences, and preclinical development. The presentation will explain SRI Biosciences core research areas - cancer, metabolic disease, inflammation, infectious disease, and neuroscience. SRI is experienced in bringing drugs to clinical trials and onto the market by partnering with industry leaders, emerging companies, and government agencies on a broad range of pharmaceutical programs.
WHEN:
Wednesday, November 17, 2010, 11:45 a.m.
WHERE:
International Congress Center -- Munich, Germany
WHO:
Walter Moos, vice president of SRI's Biosciences Division, a unique organization of more than 200 people, with all of the resources necessary to take chemical and biological research programs from "idea to IND"®— from initial discoveries to investigational new drug applications to start human clinical trials. During his career, Moos has made significant contributions to all stages of drug development, from basic research, through preclinical and clinical development, to the marketplace. Prior to joining SRI, he was Chairman and CEO of MitoKor (now Biowest). Previously, for Chiron Corporation (now Novartis) he was a corporate vice president and held positions from Director of Chemical Therapeutics to Vice President of R&D in the Technologies Division. He held various positions at the Parke-Davis Pharmaceutical Research Division of Warner-Lambert (now Pfizer), last serving as Vice President, Neuroscience and Biological Chemistry.
Moos has served on the boards of directors of more than a dozen organizations and is a co-founding member of the CEO Council, advisors to Red Abbey Venture Partners. He has served as a member of a number of academic or government advisory boards and committees. He also has edited five books, helped to found multiple scientific journals, and has about 150 publications and patents.
Moos holds a Ph.D. in chemistry from the University of California-Berkeley and received an A.B. in honors chemistry from Harvard University. He has held adjunct faculty positions at the University of Michigan, Ann Arbor, and has been an Adjunct Professor at the University of California, San Francisco since 1992 and at James Madison University since 2007.
